argenx SE

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:35:24 11/06/2026 BST			After hours 16:53:25
775.60 ^EUR	+1.65%		778.40	+0.36%

04:10pm	European Equities Traded in US as ADRs Rise in Thursday Trading	MT
06-09	Argenx SE Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM

ARGENX : Buy rating from Goldman Sachs

Published on 05/08/2026 at 12:36 pm BST

MarketScreener with dpa-AFX Analyser

ARGENX SE

+1.65%

Rajan Sharma from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price is slightly modified from 827 to 830 EUR.

Latest news about argenx SE

04:10pm	European Equities Traded in US as ADRs Rise in Thursday Trading	MT
06-09	Argenx SE Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM
06-08	William O'Neil Initiates argenx at Buy	MT
06-05	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week	MT
06-03	European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading	MT
06-03	Wall Street's Record Highs Are Starting to Look a Little Narrow
06-03	Europe set for slight retreat at the open
06-03	Europe wants to get back into the technology race
06-03	Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren?s Disease At EULAR 2026	CI
06-02	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
05-28	ARGENX : Barclays reiterates its Buy rating	ZD
05-27	Argenx Appears Confident of Rebound in Q2, RBC Says	MT
05-27	European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	MT
05-27	ARGENX : RBC reaffirms its Buy rating	ZD
05-19	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,863

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company